



In Vitro Antibiotic Susceptibility Pattern of Non-diphtheriae *Corynebacterium* Isolates in Ontario, Canada, from 2011 to 2016

Alefiya Neemuchwala,^a Deidre Soares,^a Vithusha Ravirajan,^a  Alex Marchand-Austin,^a Julianne V. Kus,^{a,b} Samir N. Patel^{a,b}

^aPublic Health Ontario Laboratory, Public Health Ontario, Toronto, Ontario, Canada

^bDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada

ABSTRACT Non-diphtheriae *Corynebacterium*-associated disease has been increasingly observed and often presents a conundrum to the treating physician. Analysis of antibiotic susceptibility testing data for 1,970 clinical *Corynebacterium* isolates received between 2011 and 2016 revealed that empirical drug treatment options are limited to vancomycin and linezolid. *Corynebacterium striatum* was the most frequently observed species during this study period, along with *C. amycolatum* and *C. pseudodiphtheriticum*/*C. propinquum*. Low levels of susceptibility to penicillin (14.5%), erythromycin (15.1%), and clindamycin (8.7%) were observed for non-diphtheriae *Corynebacterium* species, while 3.0% of isolates were not susceptible to daptomycin. Similarly, 26.9% and 38.1% of *Corynebacterium* isolates were susceptible to ciprofloxacin and trimethoprim-sulfamethoxazole, respectively. Our data show much lower susceptibility to penicillin than previously reported in the literature and an increasing number of isolates resistant to daptomycin, highlighting the need for continued antibiotic surveillance studies for appropriate patient management and treatment success.

KEYWORDS *Corynebacterium*, antibiotic resistance, penicillin resistance, susceptibility testing

Corynebacterium species are Gram-positive catalase-positive rod-shaped bacteria often referred to as “diphtheroids.” Effective vaccination programs have resulted in a decrease in *Corynebacterium diphtheriae*-related infection cases in the last 50 years. However, in the past 2 decades, there has been a rise in disease due to non-diphtheriae *Corynebacterium* species, with a variety of infections reported, including skin and soft tissue infections, prosthetic joint infections, bacteremia, respiratory infections, pneumonia, meningitis, surgical site infections, urinary tract infections, peritonitis, and endocarditis (1–3). Of additional concern, some of the non-diphtheriae *Corynebacterium* species have been shown to be resistant to multiple classes of antibiotics, thus potentially limiting effective empirical treatment (1–4).

This study presents the *in vitro* susceptibility profiles of 1,970 isolates of non-diphtheriae *Corynebacterium* species to 19 different antibiotics that were tested at the Public Health Ontario Laboratory (PHOL; Ontario, Canada) from 2011 to 2016.

RESULTS AND DISCUSSION

This study evaluated the antibiotic susceptibility test results of 1,970 isolates of nondiphtherial corynebacteria that were submitted to the PHOL from 2011 to 2016. Within this group, a total of 42 different *Corynebacterium* species were represented, as well as 24 isolates that could only be identified to the genus level and were reported as *Corynebacterium* species. The majority of the isolates belonged to *C. striatum* (47%), followed by *C. pseudodiphtheriticum*/*C. propinquum* (10.96%), *C. amycolatum* (9.64%), *C.*

Received 24 August 2017 Returned for modification 18 October 2017 Accepted 4 January 2018

Accepted manuscript posted online 16 January 2018

Citation Neemuchwala A, Soares D, Ravirajan V, Marchand-Austin A, Kus JV, Patel SN. 2018. *In vitro* antibiotic susceptibility pattern of non-diphtheriae *Corynebacterium* isolates in Ontario, Canada, from 2011 to 2016. *Antimicrob Agents Chemother* 62:e01776-17. <https://doi.org/10.1128/AAC.01776-17>.

© Crown copyright 2018. The government of Australia, Canada, or the UK (“the Crown”) owns the copyright interests of authors who are government employees. The [Crown Copyright](#) is not transferable.

Address correspondence to Samir N. Patel, samir.patel@oahpp.ca.

J.V.K. and S.N.P. contributed equally to this project.

afementans subsp. *afementans* (5%), *C. minutissimum* (4%), *C. jeikeium* (4%), *C. coyleae* (3%), and *C. urealyticum* (3%). Other *Corynebacterium* species tested during this time period included *C. resistens*, *Corynebacterium* CDC group G, *C. accolens*, *C. glucuronolyticum*, and others (see Table S1 in the supplemental material). In our study, *C. striatum* was the most commonly submitted species for identification and susceptibility testing, whereas other reports have noted *C. amycolatum* as the most prevalent nondiphtherial corynebacteria reported (1, 5). Despite being the most commonly submitted species, there was no significant difference in the proportions of *C. striatum* isolates submitted over the years ($P = 0.45$) (data not shown). Additionally, no significant trend was observed for the top five commonly encountered corynebacterial species in terms of the proportion submitted for identification and susceptibility testing over time.

Isolates were predominantly cultured from blood ($n = 479$ [24.3%]), followed by sputum ($n = 382$ [19.4%]) (Table S2). A number of isolates were also recovered from bone ($n = 97$ [4.9%]) and synovial fluid ($n = 41$ [2.0%]) (Table S2).

Between 2011 and 2016, 28 different corynebacterial species were isolated and identified from blood, with *C. striatum* as the most frequent (26.2%), followed by *C. afementans* (19.8%), *C. coyleae* (9.8%), and *C. minutissimum* (7.7%). Blood culture was the most common source for *C. mucifaciens* (92% [$n = 13$]), *C. afementans* (83% [$n = 89$]), and *C. coyleae* (81% [$n = 58$]). The most frequently recovered species from sputum specimens were *C. striatum* (63%) and *C. pseudodiphtheriticum*/*C. propinquum* (35%). For *C. striatum*, the chief specimen sources were sputum (26%), blood (14%), tissue (11%), bone (9%), wounds (6%), bronchoalveolar lavage (BAL) and/or pleural fluid (3%), and peritoneal fluid (2%).

Of the 1,970 isolates submitted for susceptibility testing, 1,010 isolates were recovered from male patients (51.3%), 739 isolates were from female patients (37.5%), and 221 specimens were from a patient of unknown sex. While 15 (0.7%) specimens were recovered from patients less than 1 year of age, 24 (1.2%) specimens were from patients age 1 to 17 years, 844 (42.8%) specimens were from patients age 18 to 64 years, and 1,070 (54.3%) specimens were from patients age 65 or older; the remaining 17 isolates did not have the patient's age on the submission form.

The susceptibility profiles of the 1,970 nondiphtherial corynebacterial isolates showed that they were universally susceptible to vancomycin and linezolid (Table 1; see also Data Set S1 in the supplemental material). The majority of isolates (>90%) were susceptible to rifampin, gentamicin, and quinupristin-dalfopristin. Interestingly, 45 out of the 1,959 isolates tested for daptomycin had an MIC of ≥ 2 mg/liter, which is considered "nonsusceptible" based on the current CLSI interpretative criteria (6). Overall as a group, the nondiphtherial corynebacteria in this study demonstrated low rates of susceptibility to penicillin (14.5%), erythromycin (15.12%), clindamycin (8.7%), and ciprofloxacin (26.9%). Based on the EUCAST clinical breakpoint (30), 27.7% of nondiphtherial corynebacterial isolates were susceptible to moxifloxacin.

Among the nondiphtherial corynebacteria in this study, *C. pseudodiphtheriticum*/*C. propinquum* isolates showed the highest susceptibility to penicillin (95.8%), whereas *C. amycolatum* (10.5%), *C. afementans* subsp. *afementans* (1.1%), *C. minutissimum* (3.9%), *C. coyleae* (1.7%), *C. urealyticum* (3.8%), and *C. aurimucosum* (5.9%) isolates were the least susceptible to penicillin (Table 1). Only a single isolate of *C. striatum* (1/931 isolates) and none of the *C. jeikeium* ($n = 76$) or *C. resistens* ($n = 19$) isolates were susceptible to penicillin. Susceptibility to penicillin and other beta-lactams has reduced in the last 2 decades among certain nondiphtherial corynebacteria, including *C. striatum* (7–10). Consistent with our findings, a study from Japan showed that none of the *C. striatum* ($n = 22$) isolates recovered from blood specimens were susceptible to penicillin (9). However, a recent Canadian study (4) reported the susceptibility rate of penicillin for the *Corynebacterium* genus to be 77%, which is much higher than the susceptibility rate (14.5%) found in our study. The difference in the susceptibility rate may be partially explained because Bernard et al. (4) used CLSI 2010 interpretative criterion (susceptibility [S], ≤ 1 mg/liter) versus the revised CLSI 2015 interpretative criterion ($S \leq 0.12$ mg/liter) for penicillin that was used in our study. Our study also did

TABLE 1 *In vitro* susceptibilities of the *Corynebacterium* isolates received at the PHOL from 2011 to 2016

| Antimicrobial agent by organism | No. of isolates | MIC range | MIC ₅₀ | MIC ₉₀ | % S ^a |
|---------------------------------|-----------------|---------------|-------------------|-------------------|------------------|
| All <i>Corynebacterium</i> spp. | 1,970 | | | | |
| Penicillin | 1,970 | ≤0.06 to >8 | 4 | >8 | 14.5 |
| Ampicillin | 1,969 | ≤0.12 to >8 | 2 | >8 | ND |
| Oxacillin | 1,969 | ≤0.25 to >4 | >4 | >4 | ND |
| Erythromycin | 1,970 | ≤0.25 to >4 | >4 | >4 | 15.1 |
| Clindamycin | 1,958 | ≤0.5 to >2 | >2 | >2 | 8.7 |
| Ciprofloxacin | 1,959 | ≤1 to >2 | >2 | >2 | 26.9 |
| Levofloxacin | 1,968 | ≤0.25 to >4 | >4 | >4 | ND |
| Moxifloxacin ^b | 1,968 | ≤0.25 to >4 | >4 | >4 | 27.7 |
| Tetracycline | 1,969 | ≤2 to >16 | ≤2 | >16 | 64.2 |
| Vancomycin | 1,970 | ≤0.25 to 2 | 0.5 | 0.5 | 100 |
| Trimethoprim-sulfamethoxazole | 1,967 | ≤0.5 to >4 | 4 | >4 | 38.1 |
| Tigecycline | 1,967 | ≤0.03 to >0.5 | 0.12 | 0.25 | ND |
| Rifampin | 1,968 | ≤0.5 to >4 | ≤0.5 | ≤0.5 | 91.4 |
| Quinupristin-dalfopristin | 1,969 | ≤0.5 to >4 | ≤0.5 | 1 | 93.3 |
| Linezolid | 1,969 | ≤1 to 2 | ≤1 | ≤1 | 100 |
| Gentamicin | 1,970 | ≤2 to >16 | ≤2 | 4 | 93.3 |
| Daptomycin | 1,959 | ≤0.5 to >4 | ≤0.5 | ≤0.5 | 97.7 |
| Chloramphenicol | 1,960 | ≤2 to >16 | 4 | >16 | ND |
| Nitrofurantoin | 1,969 | ≤32 to >64 | >64 | >64 | ND |
| <i>C. striatum</i> | 931 | | | | |
| Penicillin | 931 | ≤0.06 to >8 | 8 | >8 | 0.1 |
| Ampicillin | 930 | ≤0.12 to >8 | 4 | >8 | ND |
| Oxacillin | 930 | ≤0.25 to >4 | >4 | >4 | ND |
| Erythromycin | 931 | ≤0.25 to >4 | >4 | >4 | 14.6 |
| Clindamycin | 922 | ≤0.5 to >2 | >2 | >2 | 5.4 |
| Ciprofloxacin | 926 | ≤1 to >2 | >2 | >2 | 4.6 |
| Levofloxacin | 930 | ≤0.25 to >4 | >4 | >4 | ND |
| Moxifloxacin ^b | 929 | ≤0.25 to >4 | >4 | >4 | 5.2 |
| Tetracycline | 930 | ≤2 to >16 | >16 | >16 | 34.7 |
| Vancomycin | 931 | ≤0.25 to 1 | 0.5 | 0.5 | 100 |
| Trimethoprim-sulfamethoxazole | 928 | ≤0.5 to >4 | >4 | >4 | 11.5 |
| Tigecycline | 929 | ≤0.03 to >0.5 | 0.12 | 0.25 | ND |
| Rifampin | 930 | ≤0.5 to >4 | ≤0.5 | >4 | 85.6 |
| Quinupristin-dalfopristin | 930 | ≤0.5 to 2 | ≤0.5 | ≤0.5 | 99.4 |
| Linezolid | 930 | ≤1 | ≤1 | ≤1 | 100 |
| Gentamicin | 931 | ≤2 to >16 | ≤2 | 4 | 92.8 |
| Daptomycin | 924 | ≤0.5 to >4 | ≤0.5 | ≤0.5 | 98 |
| Chloramphenicol | 924 | ≤2 to >16 | ≤2 | 16 | ND |
| Nitrofurantoin | 930 | ≤32 to >64 | >64 | >64 | ND |
| <i>C. amycolatum</i> | 190 | | | | |
| Penicillin | 190 | ≤0.06 to >8 | 1 | >8 | 10.5 |
| Ampicillin | 190 | ≤0.12 to >8 | 1 | >8 | ND |
| Oxacillin | 190 | ≤0.25 to >4 | >4 | >4 | ND |
| Erythromycin | 190 | ≤0.25 to >4 | >4 | >4 | 15.8 |
| Clindamycin | 189 | ≤0.5 to >2 | >2 | >2 | 20.5 |
| Ciprofloxacin | 189 | ≤1 to >2 | >2 | >2 | 26.8 |
| Levofloxacin | 190 | ≤0.25 to >4 | >4 | >4 | ND |
| Moxifloxacin ^b | 190 | ≤0.25 to >4 | 4 | >4 | 27.4 |
| Tetracycline | 190 | ≤2 to >16 | ≤2 | 16 | 85.8 |
| Vancomycin | 190 | ≤0.25 to 1 | 0.5 | 0.5 | 100 |
| Trimethoprim-sulfamethoxazole | 190 | ≤0.5 to >4 | 1 | >4 | 66.8 |
| Tigecycline | 189 | ≤0.03 to >0.5 | 0.12 | 0.25 | ND |
| Rifampin | 190 | ≤0.5 to >4 | ≤0.5 | ≤0.5 | 98.4 |
| Quinupristin-dalfopristin | 190 | ≤0.5 to 2 | ≤0.5 | ≤0.5 | 99.5 |
| Linezolid | 190 | ≤1 | ≤1 | ≤1 | 100 |
| Gentamicin | 190 | ≤2 to >16 | ≤2 | 4 | 93.2 |
| Daptomycin | 190 | ≤0.5 to 2 | ≤0.5 | ≤0.5 | 99.5 |
| Chloramphenicol | 189 | ≤2 to >16 | ≤2 | 16 | ND |
| Nitrofurantoin | 190 | ≤32 to >64 | >64 | >64 | ND |

(Continued on next page)

TABLE 1 (Continued)

| Antimicrobial agent by organism | No. of isolates | MIC range | MIC ₅₀ | MIC ₉₀ | % S ^a |
|---|-----------------|---------------|-------------------|-------------------|------------------|
| <i>C. pseudodiphtheriticum/C. propinquum</i> | 216 | | | | |
| Penicillin | 216 | ≤0.06 to 4 | ≤0.06 | ≤0.06 | 95.8 |
| Ampicillin | 216 | ≤0.12 to 4 | ≤0.12 | ≤0.12 | ND |
| Oxacillin | 216 | ≤0.25 to >4 | 0.5 | 1 | ND |
| Erythromycin | 216 | ≤0.25 to >4 | >4 | >4 | 21.3 |
| Clindamycin | 216 | ≤0.5 to >2 | >2 | >2 | 20.8 |
| Ciprofloxacin | 216 | ≤1 to >2 | ≤1 | >2 | 78.7 |
| Levofloxacin | 216 | ≤0.25 to >4 | 1 | >4 | ND |
| Moxifloxacin ^b | 216 | ≤0.25 to >4 | ≤0.25 | >4 | 79.2 |
| Tetracycline | 216 | ≤2 to >16 | ≤2 | ≤2 | 98.6 |
| Vancomycin | 216 | ≤0.25 to 2 | 0.5 | 0.5 | 100 |
| Trimethoprim-sulfamethoxazole | 216 | ≤0.5 to >4 | ≤0.5 | 4 | 87.5 |
| Tigecycline | 216 | ≤0.03 to >0.5 | 0.06 | 0.25 | ND |
| Rifampin | 216 | ≤0.5 to 1 | ≤0.5 | ≤0.5 | 100 |
| Quinupristin-dalfopristin | 216 | ≤0.5 to 1 | ≤0.5 | ≤0.5 | 100 |
| Linezolid | 216 | ≤1 to 2 | ≤1 | ≤1 | 100 |
| Gentamicin | 216 | ≤2 | ≤2 | ≤2 | 100 |
| Daptomycin | 216 | ≤0.5 to >4 | ≤0.5 | ≤0.5 | 99.5 |
| Chloramphenicol | 216 | ≤2 to >16 | 4 | >16 | ND |
| Nitrofurantoin | 216 | ≤32 to >64 | >64 | >64 | ND |
| <i>C. fermentans</i> subsp. <i>fermentans</i> | 89 | | | | |
| Penicillin | 89 | ≤0.06 to >8 | 4 | >8 | 1.12 |
| Ampicillin | 89 | ≤0.12 to >8 | 4 | 8 | ND |
| Oxacillin | 89 | ≤0.25 to >4 | >4 | >4 | ND |
| Erythromycin | 89 | 2 to >4 | >4 | >4 | 0 |
| Clindamycin | 89 | 1 to >2 | >2 | >2 | 0 |
| Ciprofloxacin | 89 | ≤1 to >2 | >2 | >2 | 30.3 |
| Levofloxacin | 89 | ≤0.25 to >4 | >4 | >4 | ND |
| Moxifloxacin ^b | 89 | ≤0.25 to >4 | >4 | >4 | 31.5 |
| Tetracycline | 89 | ≤2 to >16 | ≤2 | 8 | 87.6 |
| Vancomycin | 89 | ≤0.25 to 1 | ≤0.25 | 0.50 | 100 |
| Trimethoprim-sulfamethoxazole | 89 | ≤0.5 to >4 | 2 | >4 | 55.1 |
| Tigecycline | 89 | ≤0.03 to >0.5 | 0.12 | 0.25 | ND |
| Rifampin | 89 | ≤0.5 to >4 | ≤0.5 | ≤0.5 | 94.4 |
| Quinupristin-dalfopristin | 89 | ≤0.5 to >4 | 1 | 4 | 51.7 |
| Linezolid | 89 | ≤1 to 2 | ≤1 | ≤1 | 100 |
| Gentamicin | 89 | ≤2 to >16 | ≤2 | ≤2 | 98.9 |
| Daptomycin | 89 | ≤0.5 to 4 | ≤0.5 | ≤0.5 | 97.8 |
| Chloramphenicol | 89 | ≤2 to >16 | 8 | >16 | ND |
| Nitrofurantoin | 89 | ≤32 to >64 | >64 | >64 | ND |
| <i>C. jeikeium</i> | 76 | | | | |
| Penicillin | 76 | 0.5 to >8 | >8 | >8 | 0 |
| Ampicillin | 76 | ≤0.12 to >8 | >8 | >8 | ND |
| Oxacillin | 76 | 0.5 to >4 | >4 | >4 | ND |
| Erythromycin | 76 | ≤0.25 to >4 | >4 | >4 | 11.8 |
| Clindamycin | 76 | ≤0.5 to >2 | >2 | >2 | 2.6 |
| Ciprofloxacin | 75 | ≤1 to >2 | >2 | >2 | 35.5 |
| Levofloxacin | 75 | ≤0.25 to >4 | >4 | >4 | ND |
| Moxifloxacin ^b | 76 | ≤0.25 to >4 | 4 | >4 | 35.5 |
| Tetracycline | 76 | ≤2 to >16 | ≤2 | ≤2 | 92.1 |
| Vancomycin | 76 | ≤0.25 to 2 | 0.50 | 1 | 100 |
| Trimethoprim-sulfamethoxazole | 76 | ≤0.5 to >4 | >4 | >4 | 18.4 |
| Tigecycline | 76 | ≤0.03 to >0.5 | 0.12 | 0.25 | ND |
| Rifampin | 76 | ≤0.5 to >4 | ≤0.5 | ≤0.5 | 97.4 |
| Quinupristin-dalfopristin | 76 | ≤0.5 to 4 | ≤0.5 | 2 | 89.5 |
| Linezolid | 76 | ≤1 | ≤1 | ≤1 | 100 |
| Gentamicin | 76 | ≤2 to >16 | ≤2 | >16 | 81.6 |
| Daptomycin | 75 | ≤0.5 to >4 | ≤0.5 | 1 | 89.5 |
| Chloramphenicol | 75 | ≤2 to >16 | 4 | 16 | ND |
| Nitrofurantoin | 76 | ≤32 to >64 | >64 | >64 | ND |

(Continued on next page)

TABLE 1 (Continued)

| Antimicrobial agent by organism | No. of isolates | MIC range | MIC ₅₀ | MIC ₉₀ | % S ^a |
|---------------------------------|-----------------|---------------|-------------------|-------------------|------------------|
| <i>C. minutissimum</i> | 76 | | | | |
| Penicillin | 76 | ≤0.06 to >8 | 1 | 8 | 3.9 |
| Ampicillin | 76 | ≤0.12 to >8 | 1 | 4 | ND |
| Oxacillin | 76 | 2 to >4 | >4 | >4 | ND |
| Erythromycin | 76 | ≤0.25 to >4 | >4 | >4 | 19.7 |
| Clindamycin | 76 | ≤0.5 to >2 | >2 | >2 | 1.3 |
| Ciprofloxacin | 74 | ≤1 to >2 | ≤1 | >2 | 55.3 |
| Levofloxacin | 76 | ≤0.25 to >4 | ≤0.25 | >4 | ND |
| Moxifloxacin ^b | 76 | ≤0.25 to >4 | ≤0.25 | >4 | 61.8 |
| Tetracycline | 76 | ≤2 to >16 | ≤2 | 4 | 92.1 |
| Vancomycin | 76 | ≤0.25 to 1 | 0.50 | 0.50 | 100 |
| Trimethoprim-sulfamethoxazole | 76 | ≤0.5 to >4 | 2 | >4 | 61.8 |
| Tigecycline | 76 | ≤0.03 to >0.5 | 0.06 | 0.25 | ND |
| Rifampin | 75 | ≤0.5 to >4 | ≤0.5 | ≤0.5 | 96.1 |
| Quinupristin-dalfopristin | 76 | ≤0.5 to 4 | ≤0.5 | 1 | 93.4 |
| Linezolid | 76 | ≤1 to >8 | ≤1 | ≤1 | 98.7 |
| Gentamicin | 76 | ≤2 to >16 | ≤2 | ≤2 | 96.1 |
| Daptomycin | 75 | ≤0.5 to >4 | ≤0.5 | 1 | 92.1 |
| Chloramphenicol | 75 | ≤2 to >16 | 4 | 8 | ND |
| Nitrofurantoin | 76 | ≤32 to >64 | 64 | >64 | ND |
| <i>C. coyleae</i> | 58 | | | | |
| Penicillin | 58 | ≤0.06 to >8 | 4 | >8 | 1.7 |
| Ampicillin | 58 | ≤0.12 to >8 | 4 | 8 | ND |
| Oxacillin | 58 | 2 to >4 | >4 | >4 | ND |
| Erythromycin | 58 | ≤0.25 to >4 | >4 | >4 | 3.5 |
| Clindamycin | 58 | ≤0.5 to >2 | >2 | >2 | 3.5 |
| Ciprofloxacin | 57 | ≤1 to >2 | >2 | >2 | 27.6 |
| Levofloxacin | 58 | ≤0.25 to >4 | >4 | >4 | ND |
| Moxifloxacin ^b | 58 | ≤0.25 to >4 | 4 | >4 | 29.3 |
| Tetracycline | 58 | ≤2 to >16 | ≤2 | ≤2 | 93.1 |
| Vancomycin | 58 | ≤0.25 to 2 | 0.5 | 0.50 | 100 |
| Trimethoprim-sulfamethoxazole | 58 | ≤0.5 to >4 | 4 | >4 | 48.3 |
| Tigecycline | 58 | ≤0.03 to >0.5 | 0.06 | 0.25 | ND |
| Rifampin | 58 | ≤0.5 to >4 | ≤0.5 | ≤0.5 | 91.4 |
| Quinupristin-dalfopristin | 58 | ≤0.5 to 4 | 2 | 4 | 43.1 |
| Linezolid | 58 | ≤1 to 2 | ≤1 | ≤1 | 100 |
| Gentamicin | 58 | ≤2 | ≤2 | ≤2 | 100 |
| Daptomycin | 57 | ≤0.5 to >4 | ≤0.5 | ≤0.5 | 93 |
| Chloramphenicol | 58 | ≤2 to >16 | 4 | >16 | ND |
| Nitrofurantoin | 58 | ≤32 to >64 | >64 | >64 | ND |
| <i>C. urealyticum</i> | 52 | | | | |
| Penicillin | 52 | 0.12 to >8 | >8 | >8 | 3.8 |
| Ampicillin | 52 | ≤0.12 to >8 | >8 | >8 | ND |
| Oxacillin | 52 | 1 to >4 | >4 | >4 | ND |
| Erythromycin | 52 | ≤0.25 to >4 | >4 | >4 | 1.9 |
| Clindamycin | 51 | ≤0.5 to >2 | >2 | >2 | 3.8 |
| Ciprofloxacin | 51 | ≤1 to >2 | >2 | >2 | 3.8 |
| Levofloxacin | 52 | ≤0.25 to >4 | >4 | >4 | ND |
| Moxifloxacin ^b | 52 | ≤0.25 to >4 | >4 | >4 | 3.8 |
| Tetracycline | 52 | ≤2 to >16 | ≤2 | ≤2 | 92.3 |
| Vancomycin | 52 | ≤0.25 to 2 | 0.50 | 1 | 100 |
| Trimethoprim-sulfamethoxazole | 52 | ≤0.5 to >4 | >4 | >4 | 1.9 |
| Tigecycline | 52 | ≤0.03 to >0.5 | 0.06 | 0.12 | ND |
| Rifampin | 52 | ≤0.5 to >4 | ≤0.5 | ≤0.5 | 92.3 |
| Quinupristin-dalfopristin | 52 | ≤0.5 to 1 | ≤0.5 | ≤0.5 | 100 |
| Linezolid | 52 | ≤1 | ≤1 | ≤1 | 100 |
| Gentamicin | 52 | ≤2 to >16 | ≤2 | >16 | 55.7 |
| Daptomycin | 51 | ≤0.5 | ≤0.5 | ≤0.5 | 100 |
| Chloramphenicol | 52 | ≤2 to >16 | 8 | >16 | ND |
| Nitrofurantoin | 52 | >64 | >64 | >64 | ND |

(Continued on next page)

TABLE 1 (Continued)

| Antimicrobial agent by organism | No. of isolates | MIC range | MIC ₅₀ | MIC ₉₀ | % S ^a |
|---------------------------------|-----------------|---------------|-------------------|-------------------|------------------|
| <i>C. aurimucosum</i> | 51 | | | | |
| Penicillin | 51 | 0.12 to >8 | 1 | >8 | 5.8 |
| Ampicillin | 51 | 0.25 to >8 | 1 | 8 | ND |
| Oxacillin | 51 | 2 to >4 | >4 | >4 | ND |
| Erythromycin | 51 | ≤0.25 to >4 | >4 | >4 | 11.7 |
| Clindamycin | 51 | 1 to >2 | >2 | >2 | 0 |
| Ciprofloxacin | 51 | ≤1 to >2 | >2 | >2 | 43.1 |
| Levofloxacin | 51 | ≤0.25 to >4 | 4 | >4 | ND |
| Moxifloxacin ^b | 51 | ≤0.25 to >4 | 2 | >4 | 43.1 |
| Tetracycline | 51 | ≤2 to >16 | ≤2 | 4 | 90.2 |
| Vancomycin | 51 | ≤0.25 to 1 | 0.50 | 0.50 | 100 |
| Trimethoprim-sulfamethoxazole | 51 | ≤0.5 to >4 | 2 | >4 | 62.7 |
| Tigecycline | 51 | ≤0.03 to 0.25 | 0.06 | 0.12 | ND |
| Rifampin | 51 | ≤0.5 | ≤0.5 | ≤0.5 | 100 |
| Quinupristin-dalfopristin | 51 | ≤0.5 to 4 | ≤0.5 | 1 | 92.2 |
| Linezolid | 51 | ≤1 | ≤1 | ≤1 | 100 |
| Gentamicin | 51 | ≤2 to 4 | ≤2 | ≤2 | 100 |
| Daptomycin | 51 | ≤0.5 to 3 | ≤0.5 | ≤0.5 | 98 |
| Chloramphenicol | 51 | ≤2 to >16 | 4 | 8 | ND |
| Nitrofurantoin | 51 | ≤32 to >64 | 64 | >64 | ND |

^a% S, percentage of susceptible isolates; ND, not determined.

^bEUCAST breakpoints were applied for moxifloxacin (≤0.5 mg/liter, susceptible; >0.5 mg/liter, resistant).

not include any *C. diphtheriae* isolates, which constituted 35% of the 595 isolates tested in the Bernard et al. study. Another explanation could be differences in geographical distribution of various clones of nondiphtherial corynebacteria. For example, our data demonstrate that *C. pseudodiphtheriticum*/*C. propinquum* was mostly susceptible to beta-lactams (95%); however, this differs from a report from Brazil in which high rates of penicillin resistance were observed (11). In our study, the MIC₅₀ and MIC₉₀ for ampicillin among *C. striatum* were 4 mg/liter and >8 mg/liter, respectively. On the other hand, Soriano et al. (8) reported the MIC₅₀ and MIC₉₀ values of ampicillin for *C. striatum* to be 0.5 mg/liter and 2 mg/liter, respectively, in a study conducted on isolates collected in Spain. Similarly, Martínez-Martínez et al. (12) reported the MIC₅₀ and MIC₉₀ of ampicillin for *C. striatum* (*n* = 86) of 1 mg/liter and 2 mg/liter, respectively, on isolates collected in Spain.

Susceptibility to erythromycin varied among *Corynebacterium* spp., with none of the *C. afermentans* subsp. *afermentans* isolates displaying susceptibility (*n* = 89), while only 1.9% of *C. urealyticum* and 21.2% of *C. pseudodiphtheriticum*/*C. propinquum* isolates were found to be susceptible (Table 1). Similarly, clindamycin susceptibility ranged from 0% to 20.8% among nondiphtherial corynebacteria. Resistance to erythromycin among nondiphtherial corynebacteria has been reported previously (1, 4, 7, 8) and is mainly attributed to the presence of the *ermX* gene (3). The erythromycin and clindamycin susceptibilities in this study were lower than those recently reported by Bernard et al. (4).

Among non-*diphtheriae* *Corynebacterium* species in this study, 26.9% of isolates were susceptible to ciprofloxacin. Ciprofloxacin had the lowest activity against *C. striatum* (4.6%) and *C. urealyticum* (3.8%) and the highest activity against *C. pseudodiphtheriticum*/*C. propinquum* (Table 1). The activities of moxifloxacin and levofloxacin were similar to that of ciprofloxacin for all nondiphtherial corynebacteria. *C. urealyticum* has been known to cause acute and chronic urinary tract infections (UTIs) and may lead to bacteremia. Consistent with our findings, a previous study had reported that 96.1% of *C. urealyticum* isolates were found to be nonsusceptible to ciprofloxacin (13). Fluoroquinolones are extensively used to treat UTIs (14); however, isolates of *C. urealyticum* in this study displayed resistance to several major drug classes, including ciprofloxacin. Ciprofloxacin resistance has also been reported among *C. glucuronolyticum* (15). In our study, 73% of the *C. glucuronolyticum* (*n* = 15) isolates were susceptible to ciprofloxacin.

The recent study by Bernard et al. (4) reported the rates of susceptibility to ciprofloxacin, tetracycline, and trimethoprim-sulfamethoxazole to be 69.9%, 87.1%, and 73.1%, respectively, for isolates identified as *Corynebacterium* since the 1990s (4). However, in our study, the susceptibilities among all the *Corynebacterium* isolates are lower for ciprofloxacin, tetracycline, and trimethoprim, with susceptibility rates of 27.5%, 64%, and 38%, respectively. The differences in the percentage of susceptible isolates to ciprofloxacin seen here are in line with what has been observed in other recent studies by Hahn et al. (2) and Soriano et al. (16) and may be due to differences in the number of isolates and, in particular, the years of collection.

Resistance to gentamicin has been reported previously in *C. striatum* and is associated with the presence of the *aac(3)-XI* gene encoding AAC(3)-XI, a new aminoglycoside 3-*N*-acetyltransferase (17). In our study, 92.8% of *C. striatum* isolates were found to be susceptible to gentamicin. Among all species of *Corynebacterium*, *C. urealyticum* (55.8%), *C. jeikeium* (81.2%), and *Corynebacterium* CDC group G (85.7%) showed the lowest susceptibility against gentamicin.

As stated earlier, 45 (3.0%) out of 1,959 *Corynebacterium* isolates tested for daptomycin showed an MIC of ≥ 2 mg/liter and are considered nonsusceptible isolates. Daptomycin has been increasingly suggested as an important therapeutic alternative for multidrug-resistant *Corynebacterium* species, including *C. striatum* and *C. jeikeium* (18). However, daptomycin-nonsusceptible isolates of *C. striatum* ($n = 16$), *C. minutissimum* ($n = 5$), *C. jeikeium* ($n = 7$), *C. coyleae* ($n = 3$), and a single isolate each of *C. amycolatum*, *C. aurimucosum*, *Corynebacterium* CDC group G, *C. durum*, *C. imitans*, *C. pseudodiphtheriticum*, *C. singular*, *C. simulans*, *C. riegeli*, *C. resistens*, and other *Corynebacterium* species were identified in this study. Daptomycin resistance has been previously described in *C. jeikeium* (19), as well as in patients with *C. striatum* infection receiving daptomycin treatment (20–23). Significantly, this study shows that daptomycin nonsusceptibility is not limited to *C. striatum* and *C. jeikeium* but is present in other nondiphtherial corynebacteria as well. Details regarding treatment were not available to us; therefore, it cannot be concluded if these isolates developed resistance while the patients had received treatment with daptomycin.

Tigecycline is another antibiotic that has been suggested in recent reports to be a therapeutic alternative for the treatment of complicated infections caused by these corynebacteria (24, 25). There are no breakpoints for resistance as defined by CLSI or EUCAST for tigecycline. The MIC₅₀ and MIC₉₀ were 0.12 mg/liter and 0.25 mg/liter, respectively, for all the corynebacteria in this study.

Antibiotic susceptibility testing data showed that 24 *Corynebacterium* species within the genus were completely susceptible to quinupristin-dalfopristin, and more than 90% of *C. striatum*, *C. riegeli*, *C. accolens*, *C. jeikeium*, *C. minutissimum*, *C. imitans*, *C. aurimucosum*, *Corynebacterium* CDC group G, and *C. amycolatum* isolates were susceptible. However, none of the *C. glycinophilum* ($n = 3$) isolates were susceptible to quinupristin-dalfopristin, and lower rates of susceptible isolates were found among *C. coyleae* (43%), *C. kroppenstedtii* (50%), *C. afermentans* (50%), *C. auris* (67%), and *C. tuberculostearicum* (67%).

C. minutissimum was previously considered to be susceptible to many different classes of antibiotics (1, 7, 9, 26), but most of the isolates in this study were resistant to more than four drug classes, including penicillin, erythromycin, gentamicin, and ciprofloxacin. Similarly, *C. striatum* was found to be highly multidrug resistant, with varied percentages of resistance to penicillin, erythromycin, gentamicin, ciprofloxacin, and daptomycin. Other frequently reported *Corynebacterium* species that were resistant to more than four drug classes included *C. amycolatum*, *C. aurimucosum*, *C. afermentans*, *C. jeikeium*, *C. urealyticum*, and *C. coyleae*. *C. pseudodiphtheriticum*/*C. propinquum* isolates were mostly susceptible to beta-lactams (95%), vancomycin, linezolid, tetracycline, and gentamicin, though the susceptibility to macrolides and lincosamides was greatly reduced.

Our findings demonstrate that there are differences in antibiotic susceptibility among *Corynebacterium* species and that there is considerable antibiotic resistance in

some species. Laboratories should identify clinically relevant *Corynebacterium* isolates to the species level, which may provide additional clues regarding antibiotic susceptibility. The increased use of matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) identification systems in clinical laboratories will greatly enhance front-line laboratory capacity and capability in identifying *Corynebacterium* organisms to the species level.

One of the limitations of our study is that it is not known whether *Corynebacterium* isolates recovered from specimens were truly the causative agents of the infection. The clinical relevance of nondiphtherial corynebacteria, including *C. striatum*, has been well documented since their identification (27), and *Corynebacterium* species, such as *C. striatum*, have been linked to multiple outbreaks in hospitals and nosocomial environments (28, 29). Therefore, although not often considered pathogenic, it is now clear that under the right circumstances, nondiphtherial corynebacteria can be the causative agents of infection. Therefore, in the absence of other organisms, the isolation of *Corynebacterium* spp. from sterile sites and/or from immunocompromised patients could be clinically relevant, and clinicians will need to decide whether to treat the infection based on clinical presentation as well as other findings. As nondiphtherial corynebacteria exhibit varied susceptibilities to many antibiotics, empirical treatment options are limited to vancomycin and linezolid. Multidrug resistance is on the rise among the nondiphtherial corynebacteria, with a decrease in susceptibility rates among species, such as *C. striatum* and *C. minutissimum*, which were previously reported to have low or no resistance (10, 26). As susceptibility varies among different nondiphtherial corynebacteria, and many commonly encountered *Corynebacterium* spp. are multidrug resistant, it is important to perform susceptibility testing particularly for those isolates that are recovered from sterile sites in order to manage patients appropriately. However, identification and susceptibility testing on these isolates can be time-consuming; therefore, regular surveillance studies may be useful in monitoring changes in trends of resistance and providing better empirical treatment options to patients.

MATERIALS AND METHODS

In Ontario, hospital and community laboratories generally identify *Corynebacterium* to the genus level and refer isolates that are deemed clinically significant for species-level identification and susceptibility testing to the PHOL. All isolates of nondiphtherial corynebacteria recovered from specimens received by the PHOL between 2011 and 2016 were included in the study. Since the data were deidentified prior to analysis, it is not known what the proportion of isolates is from the same patients. From 2011 to 2014, bacterial identification was primarily done by biochemical tests (3, 5), and when a definitive identification could not be made, 16S rRNA gene sequence analysis was performed. From 2015 onward, MALDI-TOF MS (MALDI BioTyper; Bruker) was primarily used for identification combined with select biochemical tests and 16S rRNA sequencing for definitive identification when needed. Prior to the implementation of MALDI-TOF MS for the identification of *Corynebacterium* spp., biochemical testing and 16S rRNA gene sequencing were unable to reliably differentiate between *C. pseudodiphtheriticum* and *C. propinquum*. As a result, these isolates were reported as *C. pseudodiphtheriticum/C. propinquum*. When a definitive species-level identification could not be made, organisms were reported out as *Corynebacterium* species (not *Corynebacterium diphtheriae*).

Antibiotic susceptibility testing was performed using commercial broth microdilution Sensititre GPALL1F plates (Trek Diagnostic Systems, Thermo Fisher Scientific), and the susceptibility results for each antibiotic were interpreted as per the Clinical and Laboratory Standards Institute (CLSI) guidelines (6). MIC testing was performed for the following antibiotics: erythromycin (0.25 to 4 mg/liter), penicillin (0.06 to 8 mg/liter), vancomycin (0.25 to 32 mg/liter), gentamicin (2 to 16 mg/liter), daptomycin (0.5 to 4 mg/liter), ciprofloxacin (1 to 2 mg/liter), moxifloxacin (0.25 to 4 mg/liter), levofloxacin (0.25 to 4 mg/liter), ampicillin (0.125 to 8 mg/liter), oxacillin (0.25 to 4 mg/liter), nitrofurantoin (32 to 64 mg/liter), rifampin (0.5 to 4 mg/liter), tigecycline (0.03 to 0.5 mg/liter), clindamycin (0.5 to 2 mg/liter), tetracycline (2 to 16 mg/liter), chloramphenicol (2 to 16 mg/liter), trimethoprim-sulfamethoxazole (0.5 to 4 mg/liter), quinupristin-dalfopristin (0.5 to 4 mg/liter), and linezolid (1 to 8 mg/liter). The CLSI does not have interpretative criteria for moxifloxacin, and therefore, clinical breakpoints for moxifloxacin were used from the European Committee for Antimicrobial Susceptibility Testing (EUCAST) (30).

The number of isolates susceptible to each antibiotic was determined per year. The Cochran-Armitage test was used to measure trends in antimicrobial resistance over time, with a *P* value of less than 0.05 considered statistically significant. The Mann-Kendall test at a 5% significance level was used to analyze trends of *Corynebacterium* species submitted over time. Statistical analyses were done using R version 3.3.2.

SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at <https://doi.org/10.1128/AAC.01776-17>.

SUPPLEMENTAL FILE 1, PDF file, 0.1 MB.

SUPPLEMENTAL FILE 2, XLSX file, 0.02 MB.

ACKNOWLEDGMENTS

We thank the staff of the reference identification and susceptibility sections of the PHOL for performing identification and susceptibility testing as part of routine clinical testing.

REFERENCES

- Funke G, von Graevenitz A, Clarridge JE, III, Bernard KA. 1997. Clinical microbiology of coryneform bacteria. *Clin Microbiol Rev* 10:125–159.
- Hahn WO, Werth BJ, Butler-Wu SM, Rakita RM. 2016. Multidrug-resistant *Corynebacterium striatum* associated with increased use of parenteral antimicrobial drugs. *Emerg Infect Dis* 22:1908–1914. <https://doi.org/10.3201/eid2211.160141>.
- Bernard K. 2012. The genus *Corynebacterium* and other medically relevant coryneform-like bacteria. *J Clin Microbiol* 50:3152–3158. <https://doi.org/10.1128/JCM.00796-12>.
- Bernard K, Pacheco AL. 2015. *In vitro* activity of 22 antimicrobial agents against *Corynebacterium* and *Microbacterium* species referred to the Canadian National Microbiology Laboratory. *Clin Microbiol Newsletter* 37:187–198. <https://doi.org/10.1016/j.clinmicnews.2015.11.003>.
- Funke G, Bernard K. 2011. Coryneform Gram-positive rods, p 413–42. *In* Versalovic J, Carroll KC, Funke G, Jorgensen JH, Landry ML, Warnock DW (ed), *Manual of clinical microbiology*, 10th ed, vol 1. ASM Press, Washington, DC.
- CLSI. 2016. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria, 3rd ed. CLSI guideline M45. Clinical and Laboratory Standards Institute, Wayne, PA.
- Funke G, Punter V, von Graevenitz A. 1996. Antimicrobial susceptibility patterns of some recently established coryneform bacteria. *Antimicrob Agents Chemother* 40:2874–2878.
- Soriano F, Zapardiel J, Nieto E. 1995. Antimicrobial susceptibilities of *Corynebacterium* species and other non-spore-forming Gram-positive bacilli to 18 antimicrobial agents. *Antimicrob Agents Chemother* 39:208–214. <https://doi.org/10.1128/AAC.39.1.208>.
- Qin L, Sakai Y, Bao R, Xie H, Masunaga K, Miura M, Hashimoto K, Tanamachi C, Hu B, Watanabe H. 2017. Characteristics of multidrug-resistant *Corynebacterium* spp. isolated from blood cultures of hospitalized patients in Japan. *Jpn J Infect Dis* 70:152–157.
- Rufael DW, Cohn SE. 1994. Native valve endocarditis due to *Corynebacterium striatum*: case report and review. *Clin Infect Dis* 19:1054–1061. <https://doi.org/10.1093/clinids/19.6.1054>.
- Camello TC, Souza MC, Martins CA, Damasco PV, Marques EA, Pimenta FP, Pereira GA, Hirata R, Jr, Mattos-Guaraldi AL. 2009. *Corynebacterium pseudodiphtheriticum* isolated from relevant clinical sites of infection: a human pathogen overlooked in emerging countries. *Lett Appl Microbiol* 48:458–464. <https://doi.org/10.1111/j.1472-765X.2009.02553.x>.
- Martínez-Martínez L, Pascual A, Bernard K, Suarez AI. 1996. Antimicrobial susceptibility pattern of *Corynebacterium striatum*. *Antimicrob Agents Chemother* 40:2671–2672.
- Salem N, Salem L, Saber S, Ismail G, Bluth MH. 2015. *Corynebacterium urealyticum*: a comprehensive review of an understated organism. *Infect Drug Resist* 8:129–145. <https://doi.org/10.2147/IDR.S74795>.
- Wagenlehner FM, Naber KG. 2006. Current challenges in the treatment of complicated urinary tract infections and prostatitis. *Clin Microbiol Infect* 12(Suppl 3):67–80. <https://doi.org/10.1111/j.1469-0691.2006.01398.x>.
- Meštrović T, Sviben M, Profožić Z, Bedenić B, Ljubić-Sternak S. 2014. Ciprofloxacin-resistant *Corynebacterium glucuronolyticum* as a cause of male urethritis syndrome. *JMM Case Rep* 2:7.
- Soriano F, Tauch A. 2008. Microbiological and clinical features of *Corynebacterium urealyticum*: urinary tract stones and genomics as the Rosetta Stone. *Clin Microbiol Infect* 14:632–643. <https://doi.org/10.1111/j.1469-0691.2008.02023.x>.
- Navas J, Fernandez-Martinez M, Salas C, Cano ME, Martinez-Martinez L. 2016. Susceptibility to aminoglycosides and distribution of *Aph* and *aac(3)-XI* genes among *Corynebacterium striatum* clinical isolates. *PLoS One* 11:e0167856. <https://doi.org/10.1371/journal.pone.0167856>.
- Navas J, Salas C, Calvo J, Martinez-Martinez L. 2012. Activity of daptomycin and three comparator agents against non-diphtheriae *Corynebacterium* isolates of clinical interest. *J Antimicrob Chemother* 67:776–778. <https://doi.org/10.1093/jac/dkr513>.
- Schoen C, Unzicker C, Stuhler G, Elias J, Einsele H, Grigoleit GU, Abele-Horn M, Mielke S. 2009. Life-threatening infection caused by daptomycin-resistant *Corynebacterium jeikeium* in a neutropenic patient. *J Clin Microbiol* 47:2328–2331. <https://doi.org/10.1128/JCM.00457-09>.
- McElvania TeKippe E, Thomas BS, Ewald GA, Lawrence SJ, Burnham CA. 2014. Rapid emergence of daptomycin resistance in clinical isolates of *Corynebacterium striatum*. . . a cautionary tale. *Eur J Clin Microbiol Infect Dis* 33:2199–2205. <https://doi.org/10.1007/s10096-014-2188-6>.
- Tran TT, Jaijakul S, Lewis CT, Diaz L, Panesso D, Kaplan HB, Murray BE, Wanger A, Arias CA. 2012. Native valve endocarditis caused by *Corynebacterium striatum* with heterogeneous high-level daptomycin resistance: collateral damage from daptomycin therapy? *Antimicrob Agents Chemother* 56:3461–3464. <https://doi.org/10.1128/AAC.00046-12>.
- Werth BJ, Hahn WO, Butler-Wu SM, Rakita RM. 2016. Emergence of high-level daptomycin resistance in *Corynebacterium striatum* in two patients with left ventricular assist device infections. *Microb Drug Resist* 22:233–237. <https://doi.org/10.1089/mdr.2015.0208>.
- Ajmal S, Saleh OA, Beam E. 2017. Development of high-grade daptomycin resistance in *Corynebacterium striatum* while on therapy. *Antimicrob Agents Chemother* 61:e00705-17. <https://doi.org/10.1128/AAC.00705-17>.
- Salas C, Calvo J, Martinez-Martinez L. 2008. Activity of tigecycline against coryneform bacteria of clinical interest and *Listeria monocytogenes*. *Antimicrob Agents Chemother* 52:1503–1505. <https://doi.org/10.1128/AAC.01129-07>.
- Fernandez-Roblas R, Adames H, Martin-de-Hijas NZ, Almeida DG, Gadea I, Esteban J. 2009. *In vitro* activity of tigecycline and 10 other antimicrobials against clinical isolates of the genus *Corynebacterium*. *Int J Antimicrob Agents* 33:453–455. <https://doi.org/10.1016/j.ijantimicag.2008.11.001>.
- Shin JY, Lee WK, Seo YH, Park YS. 2014. Postoperative abdominal infection caused by *Corynebacterium minutissimum*. *Infect Chemother* 46:261–263. <https://doi.org/10.3947/ic.2014.46.4.261>.
- Martínez-Martínez L, Suárez AI, Rodríguez-Baño J, Bernard K, Muniáin MA. 1997. Clinical significance of *Corynebacterium striatum* isolated from human samples. *Clin Microbiol Infect* 3:634–639. <https://doi.org/10.1111/j.1469-0691.1997.tb00470.x>.
- Verroken A, Bauraing C, Deplano A, Bogaerts P, Huang D, Wauters G, Glupczynski Y. 2014. Epidemiological investigation of a nosocomial outbreak of multidrug-resistant *Corynebacterium striatum* at one Belgian university hospital. *Clin Microbiol Infect* 20:44–50. <https://doi.org/10.1111/1469-0691.12197>.
- Wang J, Wang Y, Du X, Cui J, Wang K, Zhang L, Han Y. 2016. Rapid transmission of multidrug-resistant *Corynebacterium striatum* among susceptible patients in a tertiary hospital in China. *J Infect Dev Ctries* 10:1299–1305. <https://doi.org/10.3855/jidc.7577>.
- European Committee on Antimicrobial Susceptibility Testing. 2017. Breakpoint tables for interpretation of MICs and zone diameters. Version 7.1. European Committee on Antimicrobial Susceptibility Testing, Växjö, Sweden. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_7.1_Breakpoint_Tables.pdf.